TriangleBiospecimen Collection (NCT05770531)
Biospecimen Collection trial for Metastatic HER2-Negative Breast Carcinoma (NCT05770531). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults starting chemotherapy for metastatic triple-negative breast cancer, with PD-L1 combined positive score below ten or otherwise unsuitable for checkpoint inhibitors. No prior chemotherapy for metastatic disease is allowed.
The idea: random assignment compares standard imaging-guided care with blood tumor-DNA tests that may trigger an earlier switch to intravenous sacituzumab govitecan. This drug delivers a DNA-damaging payload to TROP2-bearing cells. Both groups have scans and blood collection. Researchers compare progression-free survival.
This phase 2 study plans 160 patients. Vandana Abramson leads at Vanderbilt, Nashville, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.